Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

SELL
$0.95 - $2.55 $2.51 Million - $6.75 Million
-2,647,177 Reduced 95.61%
121,479 $310 Million
Q4 2023

Feb 13, 2024

SELL
$0.74 - $1.24 $224,826 - $376,736
-303,820 Reduced 9.89%
2,768,656 $2.75 Billion
Q3 2023

Nov 13, 2023

BUY
$1.32 - $2.1 $4.06 Million - $6.45 Million
3,072,476 New
3,072,476 $4.06 Billion
Q2 2023

Aug 11, 2023

SELL
$1.75 - $2.33 $26,552 - $35,353
-15,173 Reduced 0.49%
3,072,476 $6.08 Million
Q1 2023

May 12, 2023

BUY
$1.79 - $2.87 $118,399 - $189,836
66,145 Added 2.19%
3,087,649 $5.93 Million
Q4 2022

Feb 14, 2023

BUY
$1.38 - $2.84 $66,652 - $137,169
48,299 Added 1.62%
3,021,504 $6.25 Million
Q3 2022

Nov 10, 2022

SELL
$2.19 - $3.49 $62,898 - $100,236
-28,721 Reduced 0.96%
2,973,205 $8.15 Million
Q2 2022

Aug 12, 2022

BUY
$2.6 - $3.85 $5.86 Million - $8.67 Million
2,253,224 Added 300.95%
3,001,926 $9.7 Million
Q1 2022

May 16, 2022

SELL
$2.27 - $5.1 $135,525 - $304,485
-59,703 Reduced 7.39%
748,702 $2.53 Million
Q4 2021

Feb 14, 2022

BUY
$4.21 - $7.61 $3.4 Million - $6.15 Million
808,405 New
808,405 $3.86 Million

Others Institutions Holding RZLT

About Rezolute, Inc.


  • Ticker RZLT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,827,600
  • Market Cap $186M
  • Description
  • Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultr...
More about RZLT
Track This Portfolio

Track Stonepine Capital Management, LLC Portfolio

Follow Stonepine Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Stonepine Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Stonepine Capital Management, LLC with notifications on news.